Imported unregistered methylene blue products – TGA safety advisory (2025)

Government Record · Therapeutic Goods Administration, Australian Government Department of Health, Disability and Ageing · September 25, 2025

Therapeutic Goods Administration et al., 2025-09-25: TGA's 25 September 2025 advisory warns about imported, unregistered oral methylene blue sold for cognitive enhancement, mood and anti-ageing claims, notes that methylene blue is prescription-only when presented for injection, and lists serotonin syndrome, pregnancy risk and G6PD haemolysis as the key hazards.

The Therapeutic Goods Administration (TGA) is issuing a safety advisory about the increasing importation and use of unregistered oral methylene blue (methylthioninium chloride) products in Australia.

Therapeutic Goods Administration et al., 2025-09-25: TGA's 25 September 2025 advisory warns about imported, unregistered oral methylene blue sold for cognitive enhancement, mood and anti-ageing claims, notes that methylene blue is prescription-only when presented for injection, and lists serotonin syndrome, pregnancy risk and G6PD haemolysis as the key hazards. C8 – the supplement/research-chemical channel, documented by a regulator rather than by a vendor. Same page, verbatim: 'These products are being promoted for unapproved (off-label) uses, such as cognitive enhancement, mood improvement, and anti-ageing effects. They have not been assessed by us for quality, safety or efficacy as required under Australian legislation.' and 'Although methylene blue products are only prescription-only when presented for injection, they are not without significant risks when used orally.' No vendor, brand or price is named. Fetch route: web_extract (tga.gov.au blocks plain curl). Study type: regulatory record.